Translate AMICOR contents if you like

Showing posts with label Parkinson. Show all posts
Showing posts with label Parkinson. Show all posts

Thursday, August 29, 2019

New Parkinson's Drug

New Parkinson's Drug Approved

— Treatment improves "off" time when used as add-on

SILVER SPRING, Md. – The FDA approved istradefylline (Nourianz) as an add-on treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing "off" episodes, the agency announced late Tuesday.
Istradefylline is an orally administered, selective adenosine A2Areceptor antagonist and has been marketed in Japan since 2013 as adjunctive treatment to levodopa-containing products for Parkinson's patients.

Monday, July 02, 2018

NLY01 Exenatide, Lixisenatide, liraglutide and dulaglutide in PD

Experimental Drug Stops Parkinson’s Progression: Mouse Study

by Neuroscience News
A newly developed experimental drug, that contains similar compounds to those in diabetes medications, slows the progression of Parkinson's in mouse models of the disease, researchers report.
Similar drugs to NLY01 already approved by the Food and Drug Administration for the treatment of type 2 diabetes include exenatide, lixisenatide, liraglutide and dulaglutide, each of which can cost approximately $2,000 for a 90-day supply. NLY01 is a long-acting drug with improved the brain penetration compared to these approved drugs for diabetes.

Wednesday, February 21, 2018

Parkinson's Disease


Flushing out 'zombie cells' could help stave off Parkinson's, study suggests

Possible approach to treating effects of neurodegenerative diseases – and even ageing – revealed by trial
Senescent cells lose a specific protein from their nuclei, indicated by the green colour above. This protein is lost from astrocytes (red cells), but not from neighbouring cells.
 Senescent cells lose a specific protein from their nuclei, indicated by the green colour above. This protein is lost from astrocytes (red cells), but not from neighbouring cells. Photograph: Georgia Woods, PhD Buck Institute for Research on Aging
In work that could open a new front in the war on Parkinson’s disease, and even ageing itself, scientists have shown that they can stave off some of the effects of the neurodegenerative disease by flushing “zombie cells” from the brain.
The research in mice raises hopes for a fresh approach to treating the most common forms of Parkinson’s disease, which typically arise through a complex interplay of genetics, lifestyle and potentially toxic substances in the environment.
But the approach may have benefits far beyond Parkinson’s, with other neurodegenerative diseases – and the ageing process more broadly – all being linked to the ill effects of these “senescent” cells, which linger in tissues after entering a state of suspended animation in the body./.../
...........................................
Study suggests that exenatide, currently used to treat type 2 diabetes, improves movement-related issues and might also slow the progression of the disease
A drug commonly used to treat diabetes could help those living with Parkinson’s disease, research has revealed.
By 2020 it is predicted that 162,000 individuals in the UK will be living with the condition. While existing drugs help to control its symptoms, there are currently none available which slow or halt its progression.
But now scientists say they have found that a drug commonly used to treat type 2 diabetes appears to improve movement-related issues. 
The benefit persisted even when the drug had not been taken for 12 weeks, suggesting it might be helping to slow the progression of the disease./.../

Monday, February 19, 2018

Calcium and Parkinson's D


Calcium May Play a Role in the Development of Parkinson’s

by Neuroscience News
A new Nature Communications study reveals increased calcium levels in brain cells may play a significant role in the development of Parkinson's disease.
Neuroscience News | February 19, 2018 at 9:47 am | Tags: alpha-synucleindSTORMSUVs | URL: https://wp.me/p4sXNK-cbj
Comment   See all comments

Thursday, June 15, 2017

Parkinson’s & Gut Endocrine Cells


Study Suggests Parkinson’s Could Start in Gut Endocrine Cells

by Neuroscience News
Researchers suggest an agent in the gut could interfere with alpha-synuclein in endocrine cells, deforming the proteins which then may spread to the brain in Parkinson's patients.
Neuroscience News | June 15, 2017 at 11:20 am | Tags: alpha-synucleinEECsgut-brain axisSTC-1 | URL: http://wp.me/p4sXNK-aOV
Comment   See all comments

Sunday, November 11, 2012

Alzheimer


New stem-cell-derived cells hold promise for Alzheimer’s, other brain diseases

November 9, 2012
Choroid plexus epithelial cells generated in a culture medium using embryonic stem cells
 (credit: Edwin S. Monuki and Momoko Watanabe/USPTO)
UC Irvine researchers have created a new stem cell-derived cell type with unique promise for treating neurodegenerative diseases such as Alzheimer’s.
Dr. Edwin Monuki of UCI’s Sue & Bill Gross Stem Cell Research Center and colleagues developed these cells — called choroid plexus epithelial cells (CPECs) — from existing mouse and human embryonic stem cell lines.
CPECs are critical for proper functioning of the choroid plexus, the tissue in the brain that produces cerebrospinal fluid (CSF ).  CPECs make CSF and remove metabolic waste and foreign substances from the fluid and brain, among other tasks.
In neurodegenerative diseases, the choroid plexus and CPECs age prematurely, resulting in reduced CSF formation and decreased ability to flush out the plaque-forming proteins that are a hallmark of Alzheimer’s. Transplant studies have provided proof of concept for CPEC-based therapies. However, such therapies have been hindered by the inability to expand or generate CPECs in culture.
“Our method is promising, because for the first time we can use stem cells to create large amounts of these epithelial cells, which could be utilized in different ways to treat neurodegenerative diseases,” said Monuki, an associate professor of pathology & laboratory medicine and developmental & cell biology at UCI.
To create the new cells, Monuki and his colleagues coaxed embryonic stem cells to differentiate into immature neural stem cells. They then developed the immature cells into CPECs capable of being delivered to a patient’s choroid plexus.
These cells could be part of neurodegenerative disease treatments in at least three ways, Monuki said. First, they’re able to increase the production of CSF to help flush out plaque-causing proteins from brain tissue and limit disease progression. Second, CPEC “superpumps” could be designed to transport high levels of therapeutic compounds to the CSF, brain and spinal cord. Third, these cells can be used to screen and optimize drugs that improve choroid plexus function.
Monuki said the next steps are to develop an effective drug screening system and to conduct proof-of-concept studies to see how these CPECs affect the brain in mouse models of Huntington’s, Alzheimer’s and pediatric diseases.
The study as supported by the National Institutes of Health, the California Institute for Regenerative Medicine, UCI’s Institute for Clinical & Translational Science, and UCI’s Alzheimer’s Disease Research Center.


Friday, December 23, 2011

Parkinson's Disease


December 21, 2011 — Phosphorylated alpha-synuclein, which may be detected in blood plasma, shows promise as a diagnostic biomarker for Parkinson's disease (PD), researchers report in the December issue of the Journal of the Federation of American Societies for Experimental Biology (the FASEB Journal).
Alpha-synuclein is believed to play a "pivotal role" role in the development of the synucleinopathies, PD, and dementia with Lewy bodies (DLB), Penelope G. Foulds, PhD, from the University of Lancaster, United Kingdom, and colleagues note in their report.
The fact that this protein is present in human body fluids, including cerebrospinal fluid (CSF) and blood plasma, has fueled interest in its use as a biomarker for PD. However, most studies to date have relied on immunoassays that do not distinguish between monomeric/oligomeric and nonphosphorylated/phosphorylated forms of the protein, the researchers say/.../
.

Thursday, May 26, 2011

Suspect bacterium may trigger Parkinson’s

Mouse study finds stomach ulcer-causing microbes may also affect brain
Web edition : Sunday, May 22nd, 2011
  Text Size
NEW ORLEANS — Brain cells may be the latest victim of a bacterial bad guy already charged with causing ulcers and stomach cancer.
Helicobacter pylori, a bacterium that lives in the stomachs of about half the people in the world, may help trigger Parkinson’s disease, researchers reported May 22 at a meeting of the American Society for Microbiology. Parkinson’s disease is a neurological disorder that kills dopamine-producing cells in some parts of the brain. People with the disease have trouble controlling their movements. About 60,000 new cases of the disease are diagnosed each year in the United States./.../

Friday, January 07, 2011

Simple Question Aids Parkinson's Diagnosis

By John Gever, Senior Editor, MedPage Today
Published: January 06, 2011
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco.

Dutch researchers said they have found a way to distinguish atypical Parkinson's disease from the more common standard form: asking patients if they can still ride a bicycle.

When the question was put to 111 consecutive patients with Parkinson's disease, nearly all those who said it had become impossible were subsequently determined to have the atypical form, according to Bastiaan Bloem, PhD, and colleagues at Nijmegen Medical Center in the Netherlands.

"Simply asking about cycling abilities could be added to the list of red flags that can assist clinicians in their early differential diagnosis of parkinsonism," they reported in the Jan. 8 issue of The Lancet./.../

Monday, November 10, 2008

Gout May Protect Against Risk of Parkinson's Disease

VANCOUVER, British Columbia, Nov. 7 -- Patients with gout were less likely to develop Parkinson's disease, a cohort study found, supporting the purported protective role of uric acid.

The risk of Parkinson's disease was 30% lower among patients with a history of gout, independent of age, sex, prior medical conditions, and the use of diuretics, Hyon Choi, M.D., of the University of British Columbia, and colleagues reported online in Arthritis Care & Research.

Several epidemiologic studies have suggested that higher serum uric acid levels lead to a lower risk of Parkinson's disease, possibly because uric acid exerts antioxidant effects on neurons, the investigators said.

Uric acid can scavenge superoxide, hydroxyl radical, and singlet oxygen, as well as chelate transition metals, they said. With these antioxidant properties, uric acid has been hypothesized to protect against oxidative stress, a prominent contributor to dopaminergic neuron degeneration in Parkinson's disease./.../